Three more to go. Testing new concepts.
J.P. Morgan also cuts rating.
Spar spends EUR 2.5 mn on them.
It does not plan expansion, either.
U.S. FDA rejects application by Allergan.
Plaza ban is now stricter.
Profit was up by a third.
Q2 earnings report to be released on Wednesday.